Hemodynamic Effects of Spironolactone in Patients With Heart Failure

To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action.

Randomized, two group placebo controlled, single blind study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Congestive Heart Failure Cardiovascular Diseases Heart Diseases Heart Failure

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University of Ohio

Toledo, Ohio, 43614, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CHF
21 - 80 years
Serum creatinine < 2 mg/dL
Serum potassium 2.7 - 4.5 mg/dL measured within past 4 weeks

Exclusion criteria

Less than 21 years
Pregnancy

Treatment and study plan

Spironolactone

Drug

100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.

Primary outcomes

Echocardiogram

Time frame: 3 measurements 15 minutes apart before drug and 15 minutes for 2 hours after drug
Measure of Kidney function and potassium levels

Time frame: This will be taken before drug, two hours after and the following day

Sponsors and collaborators

Lead sponsor

University of Toledo Health Science Campus

Other

Registry information

Important dates

Study start: 2003
Primary completion: 2006
Study completion: 2006
First posted: Mar 12, 2009
Registry last updated: Dec 10, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed